AlphAIAlphAI — Financial news for AI agents
tradingview.com$DCTH

Delcath Systems 3Q 2026: Revenue $35.1M, EPS $0.17 — 10-Q Summary

Delcath Systems reported Q3 2026 revenue of $35.1M, up 70.7% YoY, and net income of $6.95M, up 737.6% YoY. Growth was driven by increased demand for HEPZATO KIT and commercial expansion. Operating expenses rose due to higher R&D and commercial spending. The company also began a Phase 2 trial for HEPZATO in metastatic breast cancer.

Original reporting
tradingview.com
Published Nov 9, 2026, 2:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 2:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Delcath Systems 3Q 2026: Revenue $35.1M, EPS $0.17 — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$DCTHBullishMed
01

Why it matters

The earnings release provides fresh quantitative data on sales growth and profitability, offering a basis for short‑term trading decisions.

02

Market read

First‑time disclosure of quarterly results for a micro‑cap biotech, offering actionable insight for traders focused on earnings catalysts.

03

What to watch

Rising R&D expenses and SG&A may pressure margins in upcoming quarters.

Relevance 7/10Novelty 8/10Timing: post‑earnings today

Background

Delcath Systems filed its Form 10‑Q for Q3 2026, highlighting revenue growth driven by HEPZATO sales and expansion in the U.S.

Company-level read

Ticker impact

$DCTHBullishHigh confidence
Context

Delcath Systems reported Q3 2026 revenue of $35.1M and EPS $0.17, a 70% YoY revenue increase.

Expected impact

upward pressure as market prices in the earnings beat

Evidence & confidence

Revenue and net income surged YoY, indicating improved commercial traction for HEPZATO.

Market effects

Sector

Positive signal for the oncology drug delivery sector and related biotech peers.

Regional

U.S. biotech market may see modest uplift.

Global

Limited to niche oncology therapeutics market.

Counterpoint

What could challenge this read

Despite the beat, the small absolute size and high cash burn could limit upside.

Key entities

  • company
    Delcath Systems, Inc.

    Biotech firm developing hepatic drug delivery technologies.

Read at source← All news

StoryDelcath Systems posts Q3 2026 results, lifts full‑year revenue guidance

Also covered by

4 outlets

Related articles

$DCTHHighAI 8/10

Delcath Systems Inc (DCTH) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised

Delcath Systems (DCTH) reported Q3 2026 revenue of $35.1M, up 71% YoY, driven by HEPZATO KIT sales. CEO Gerard Michel cited therapy adoption, physician demand, and expanded capacity as growth drivers. The company raised full-year revenue guidance to $115M-$117M. Q4 guidance implies a step-down due to holiday impact, with new patient starts expected to slow. The Phase II colorectal cancer trial interim analysis is now expected in Q2 or Q3 2027.

finance.yahoo.com
$EDSAMedAI 8/10

Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain

Edesa Biotech (EDSA) and Delcath Systems (DCTH) shares rose 30% after signing a licensing deal and reporting strong Q3 results, respectively. Immunovant (IMVT) and Vir Biotechnology (VIR) shares gained 13% and 14% following positive clinical trial data. EDSA received $12M upfront, DCTH raised FY26 revenue outlook, IMVT met primary endpoint, and VIR showed undetectable HDV RNA in 28 patients.

rttnews.com
$DCTHMed

Delcath (DCTH) Q3 2026 Earnings Call Transcript

Delcath (DCTH) reported Q3 2026 revenue of $35.1M, up 71% YoY, driven by HEPZATO KIT adoption. The company added new treatment centers, including AdventHealth, and expects 36 centers by year-end. Clinical trials are progressing, with a Phase II colorectal trial on track for interim analysis in mid-2027. Full-year revenue guidance was raised to $115M-$117M, with Q4 expected to grow 25%-34% YoY.

finance.yahoo.com
$DCTHMed

Delcath Systems Reports 70% Revenue Growth in Q3 2026 and Raises Full-Year Guidance to $115 Million–$117 Million

Delcath Systems (DCTH) reported Q3 2026 revenue of $35.1M, up 70% YoY, driven by higher sales of its liver cancer treatment products. The company raised its full-year revenue guidance to $115M–$117M. Net income increased to $7.0M, and gross margin improved to 89%. HEPZATO KIT revenue grew 69% to $32.7M, while European CHEMOSAT revenue rose to $2.4M. Adjusted EBITDA increased to $11.5M, and operating cash flow reached $8.2M. Delcath also advanced its clinical development programs.

finance.yahoo.com
$DCTHMed

Delcath Systems Q3 Earnings Call Highlights

Delcath Systems (DCTH) raised its 2026 revenue guidance to $115M-$117M, projecting HEPZATO KIT volume growth of at least 41% over 2025. Q4 revenue is expected to be $25.8M-$27.8M, down sequentially but up 25%-34% year-over-year, due to holiday scheduling. Growth is attributed to increased use of HEPZATO, patient awareness, and expanded capacity at centers like MD Anderson and Mass General.

finance.yahoo.com